Revolutionary Lifileucel Therapy: A New Era in Metastatic Melanoma Treatment
The recent FDA accelerated approval of lifileucel, known commercially as Amtagvi, marks a groundbreaking development in cancer therapy. This treatment is the first of its kind, a tumor-derived autologous T cell immunotherapy, specifically targeting patients with unresectable or metastatic melanoma who have undergone prior treatments. This
Read More
